Search
Elotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. … Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … It is currently available under the brand name Removab.
Peramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalPeramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.
Products: Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (3 Adet), Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (5 Adet)Bendamustine
go.drugbank.com/drugs/DB06769ApprovedInvestigationalBendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). … It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: BEN SPAL-P® 25, PURPULZ ® 180 MG/4 MLTesamorelin
go.drugbank.com/drugs/DB08869ApprovedInvestigationalLipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection. … Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients
Synonyms: N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet), GHRH(1-44)Products: Egrifta SvInositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnIt is used in food supplements as a source of niacin (vitamin B3), where hydrolysis of 1 g (1.23 mmol) inositol hexanicotinate yields 0.91 g nicotinic acid and 0.22 g inositol. … Inositol nicotinate, also known as Inositol hexaniacinate/hexanicotinate or "no-flush niacin", is a niacin ester and vasodilator.
Categories: Vitamin B Complex, Heterocyclic Compounds, 1-RingVorapaxar
go.drugbank.com/drugs/DB09030ApprovedVorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history … By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle, Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl esterAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). … It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalAnthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. … It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified.
Edoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalEdoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. … It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-Ring